All News

Achieving undetectable minimal residual disease (MRD) status is important for deep and durable responses in patients with chronic lymphocytic leukemia (CLL), according to 2 abstracts presented at the 2019 American Society of Clinical Oncology Annual Meeting.

While minimal residual disease (MRD) is being used to assess response to treatment in multiple myeloma (MM), the level of risk a patient has can make a big different in how well MRD works as a prognostic indicator, according to 2 abstracts presented at the 2019 American Society of Clinical Oncology Annual Meeting.

This week, the top managed care news included President Trump issuing an executive order for more healthcare transparency; provisional data indicating that overdose deaths may be falling; the Supreme Court agreeing to hear insurers' Affordable Care Act lawsuit.

A report released Thursday from the National Academies of Sciences, Engineering, and Medicine said the United States needs a US National Cancer Control Plan that uses a system approach to reshape cancer control efforts, targeting everything from prevention, machine learning, palliative care, assessing value, rooting out financial conflicts of interest, and more.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo